NICE Technology Appraisal Guidance No.59; The clinical effectiveness and cost effectiveness of electroconvulsive therapy (ECT) for depressive illness, schizophrenia, catatonia and mania

Static List Review

TA59; The clinical effectiveness and cost effectiveness of electroconvulsive therapy (ECT) for depressive illness, schizophrenia, catatonia and mania was added to the static list in January 2008.

Guidance is moved to the static list following consultation with consultees and commentators when it is clear that there is no new research available that would have any material effect on the current guidance. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

As the appraisal has been on the static list for more than 5 years, NICE has been gathering intelligence to ascertain whether there is any new evidence available relevant to this appraisal and whether this should be considered through the full review proposal process.

There is no new evidence available that would lead to a change in the existing recommendations.  The only research that post-dates the decision to place TA 59 on the static list relates to depression, which has been updated by CG90 (Depression: the treatment and management of depression in adults).

As a result, we have decided that TA59 should remain on the static list and no further action is required at this time.

However, if NICE is notified of a significant change to the evidence base at any stage in the future, this could trigger a formal review proposal.

April 2014

Attachments